Fig. 1: Schematic representation of liver stage arresting GAPs that have or will soon be tested in clinical trials.

Length of development of each GAP in relation to protection in humans is shown. Candidates include the early arresters GA1 (PfΔb9Δslarp), 2KO (PfΔp36Δp52) and 3KO (PfΔp36Δp52Δsap1). GA2 (PfΔmei2) and LARC2 (Pf Δmei2Δlinup) are late arresters.